|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and Major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Poulogiannis G, Ichimura K, Hamoudi RA,
Luo F, Leung SY, Yuen ST, Harrison DJ, Wyllie AH and Arends MJ:
Prognostic relevance of DNA copy number changes in colorectal
cancer. J Pathol. 220:338–347. 2010. View Article : Google Scholar
|
|
4
|
Arends MJ: Pathways of colorectal
carcinogenesis. Appl Immunohistochem Mol Morphol. 21:97–102.
2013.PubMed/NCBI
|
|
5
|
Ibrahim AE, Arends MJ, Silva AL, Wyllie
AH, Greger L, Ito Y, Vowler SL, Huang TH, Tavaré S, Murrell A and
Brenton JD: Sequential DNA methylation changes are associated with
DNMT3B overexpression in colorectal neoplastic progression. Gut.
60:499–508. 2011. View Article : Google Scholar
|
|
6
|
Falzone L, Salomone S and Libra M:
Evolution of cancer pharmacological treatments at the turn of the
third millennium. Front Pharmacol. 9:13002018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ganesh K, Stadler ZK, Cercek A, Mendelsohn
RB, Shia J, Segal NH and Diaz LA Jr: Immunotherapy in colorectal
cancer: Rationale, challenges and potential. Nat Rev Gastroenterol
Hepatol. 16:361–375. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kalyan A, Kircher S, Shah H, Mulcahy M and
Benson A: Updates on immunotherapy for colorectal cancer. J
Gastrointest Oncol. 9:160–169. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Copur MS: Immunotherapy in colorectal
cancer. Oncology (Williston Park). 33:6865062019.
|
|
10
|
Abakushina EV, Gelm YV, Pasova IA and
Bazhin AV: Immunotherapeutic approaches for the treatment of
colorectal cancer. Biochemistry (Mosc). 84:720–728. 2019.
View Article : Google Scholar
|
|
11
|
Dawood S: The evolving role of immune
oncology in colorectal cancer. Chin Clin Oncol. 7:172018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Christofi T, Baritaki S, Falzone L, Libra
M and Zaravinos A: Current perspectives in cancer immunotherapy.
Cancers (Basel). 11:E14722019. View Article : Google Scholar
|
|
13
|
Koi M and Carethers JM: The colorectal
cancer immune micro-environment and approach to immunotherapies.
Futur Oncol. 13:1633–1647. 2017. View Article : Google Scholar
|
|
14
|
Chen DS and Mellman I: Elements of cancer
immunity and the cancer-immune set point. Nature. 541:321–330.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen DS and Mellman I: Oncology meets
immunology: The cancer-immunity cycle. Immunity. 39:1–10. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ayiomamitis GD, Notas G, Vasilakaki T,
Tsavari A, Vederaki S, Theodosopoulos T, Kouroumalis E and
Zaravinos A: Understanding the interplay between COX-2 and hTERT in
colorectal cancer using a multi-omics analysis. Cancers (Basel).
11:E15362019. View Article : Google Scholar
|
|
17
|
Zaravinos A, Roufas C, Nagara M, de Lucas
Moreno B, Oblovatskaya M, Efstathiades C, Dimopoulos C and
Ayiomamitis GD: Cytolytic activity correlates with the mutational
burden and deregulated expression of immune checkpoints in
colorectal cancer. J Exp Clin Cancer Res. 38:3642019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Roufas C, Chasiotis D, Makris A,
Efstathiades C, Dimopoulos C and Zaravinos A: The expression and
prognostic impact of immune cytolytic activity-related markers in
human malignancies: A comprehensive meta-analysis. Front Oncol.
8:272018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang Z, Kang B, Li C, Chen T and Zhang Z:
GEPIA2: An enhanced web server for large-scale expression profiling
and interactive analysis. Nucleic Acids Res. 47:W556–W560. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Charoentong P, Finotello F, Angelova M,
Mayer C, Efremova M, Rieder D, Hackl H and Trajanoski Z: Pan-cancer
immunogenomic analyses reveal genotype-immunophenotype
relationships and predictors of response to checkpoint blockade.
Cell Rep. 18:248–262. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cancer Genome Atlas Network: Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Goldman M, Craft B, Hastie M, Repečka K,
Kamath A, McDade F, Rogers D, Brooks AN, Zhu J and Haussler D: The
UCSC Xena platform for public and private cancer genomics data
visualization and interpretation. bioRxiv. 3264702019.
|
|
23
|
Guinney J, Dienstmann R, Wang X, de
Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda
G, Angelino P, et al: The consensus molecular subtypes of
colorectal cancer. Nat Med. 21:1350–1356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Giannakis M, Mu XJ, Shukla SA, Qian ZR,
Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, et
al: Genomic correlates of immune-cell infiltrates in colorectal
carcinoma. Cell Rep. 15:857–865. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Swann JB and Smyth MJ: Immune surveillance
of tumors. J Clin Invest. 117:1137–1146. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ribatti D: The concept of immune
surveillance against tumors. The first theories. Oncotarget.
8:7175–7180. 2017. View Article : Google Scholar
|
|
27
|
Boland PM and Ma WW: Immunotherapy for
colorectal cancer. Cancers (Basel). 9:E502017. View Article : Google Scholar
|
|
28
|
Fan J, Shang D, Han B, Song J, Chen H and
Yang JM: Adoptive cell transfer: Is it a promising immunotherapy
for colorectal cancer? Theranostics. 8:5784–5800. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baek JH and Kim KJ: Expansion of
tumor-infiltrating lymphocytes and their potential for application
to adoptive cell therapy in patients with colorectal cancer. Eur J
Surg Oncol. 45:e58–e59. 2019. View Article : Google Scholar
|
|
30
|
Kodumudi KN, Siegel J, Weber AM, Scott E,
Sarnaik AA and Pilon-Thomas S: Immune checkpoint blockade to
improve tumor infiltrating lymphocytes for adoptive cell therapy.
PLoS One. 11:e01530532016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Edin S, Wikberg ML, Dahlin AM, Rutegård J,
Öberg Å, Oldenborg PA and Palmqvist R: The distribution of
macrophages with a M1 or M2 phenotype in relation to prognosis and
the molecular characteristics of colorectal cancer. PLoS One.
7:e470452012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Narayanan S, Kawaguchi T, Peng X, Qi Q,
Liu S, Yan L and Takabe K: Tumor infiltrating lymphocytes and
macrophages improve survival in microsatellite unstable colorectal
cancer. Sci Rep. 9:134552019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao Y, Ge X, Xu X, Yu S, Wang J and Sun
L: Prognostic value and clinicopathological roles of phenotypes of
tumour-associated macrophages in colorectal cancer. J Cancer Res
Clin Oncol. 145:3005–3019. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rosenbaum MW, Bledsoe JR, Morales-Oyarvide
V, Huynh TG and Mino-Kenudson M: PD-L1 expression in colorectal
cancer is associated with microsatellite instability, BRAF
mutation, medullary morphology and cytotoxic tumor-infiltrating
lymphocytes. Mod Pathol. 29:1104–1112. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fabrizio DA, George TJ Jr, Dunne RF,
Frampton G, Sun J, Gowen K, Kennedy M, Greenbowe J, Schrock AB,
Hezel AF, et al: Beyond microsatellite testing: Assessment of tumor
mutational burden identifies subsets of colorectal cancer who may
respond to immune checkpoint inhibition. J Gastrointest Oncol.
9:610–617. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chan TA, Yarchoan M, Jaffee E, Swanton C,
Quezada SA, Stenzinger A and Peters S: Development of tumor
mutation burden as an immunotherapy biomarker: Utility for the
oncology clinic. Ann Oncol. 30:44–56. 2019. View Article : Google Scholar :
|
|
37
|
Yarchoan M, Albacker LA, Hopkins AC,
Montesion M, Murugesan K, Vithayathil TT, Zaidi N, Azad NS, Laheru
DA, Frampton GM and Jaffee EM: PD-L1 expression and tumor
mutational burden are independent biomarkers in most cancers. JCI
Insight. 4:1269082019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lal N, Beggs AD, Willcox BE and Middleton
GW: An immunogenomic stratification of colorectal cancer:
Implications for development of targeted immunotherapy.
Oncoimmunology. 4:e9760522015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hamada T, Soong TR, Masugi Y, Kosumi K,
Nowak JA, da Silva A, Mu XJ, Twombly TS, Koh H, Yang J, et al: TIME
(Tumor Immunity in the MicroEnvironment) classification based on
tumor CD274 (PD-L1) expression status and tumor-infiltrating
lymphocytes in colorectal carcinomas. Oncoimmunology.
7:e14429992018. View Article : Google Scholar :
|
|
40
|
Xie S, Huang J, Qiao Q, Zang W, Hong S,
Tan H, Dong C, Yang Z and Ni L: Expression of the inhibitory B7
family molecule VISTA in human colorectal carcinoma tumors. Cancer
Immunol Immunother. 67:1685–1694. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee SJ, Byeon SJ, Lee J, Park SH, Park JO,
Park YS, Kang WK, Lim HY, Kim KM and Kim ST: LAG3 in solid tumors
as a potential novel immunotherapy target. J Immunother.
42:279–283. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou G, Noordam L, Sprengers D, Doukas M,
Boor PPC, van Beek AA, Erkens R, Mancham S, Grünhagen D, Menon AG,
et al: Blockade of LAG3 enhances responses of tumor-infiltrating T
cells in mismatch repair-proficient liver metastases of colorectal
cancer. Oncoimmunology. 7:e14483322018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Schrock AB, Ouyang C, Sandhu J, Sokol E,
Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, et al: Tumor
mutational burden is predictive of response to immune checkpoint
inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol.
30:1096–1103. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ogino S, Nosho K, Irahara N, Meyerhardt
JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M,
Tanaka N, et al: Lymphocytic reaction to colorectal cancer is
associated with longer survival, independent of lymph node count,
microsatellite instability, and CpG island methylator phenotype.
Clin Cancer Res. 15:6412–6420. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jass JR: Lymphocytic infiltration and
survival in rectal cancer. J Clin Pathol. 39:585–589. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schumacher TN and Schreiber RD:
Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Brown SD, Warren RL, Gibb EA, Martin SD,
Spinelli JJ, Nelson BH and Holt RA: Neo-antigens predicted by tumor
genome meta-analysis correlate with increased patient survival.
Genome Res. 24:743–750. 2014. View Article : Google Scholar : PubMed/NCBI
|
